Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
101991-8 3-hydroxypropyl mercapturate MRto Urine Pt Qn     ACTIVE 3-hydroxypropyl mercapturate [Mass Ratio] in Urine   NAM DefinitionDescription     ug/g creatinine             CHEM   101991-8         Both       0 3-HPMA Ur       N   3-HPMA; Chemistry; III; L-Cysteine, N-acetyl-S-(3-hydroxypropyl); Mass concentration ratio; Mass ratio; MCRto; N-Acetyl-S-(3-hydroxypropyl)cysteine; Point in time; QNT; Quan; Quant; Quantitative; Random; S-(3-Hydroxypropyl)cysteine N-acetate; UA; UR; Urn 2.77 2.75               ug/g{creat}     Release 2.77: COMPONENT: changed to the anionic name per the Users' Guide section 2.1.2.13; 0
101992-6 Quinolinate MRto Urine Pt Qn     ACTIVE Quinolinate [Mass Ratio] in Urine   ADD DefinitionDescription     ug/g creatinine             CHEM   101992-6         Both       0 Quinolinate Ur       N   Chemistry; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Tryptophan metabolite; UA; UR; Urn 2.75 2.75               ug/g{creat}       0
101993-4 Kynurenate MRto Urine Pt Qn     ACTIVE Kynurenate [Mass Ratio] in Urine   ADD DefinitionDescription     ug/g creatinine             CHEM   101993-4         Both       0 KYN Ur       N   Chemistry; KYN; KYNA; Kynurenic acid; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn 2.75 2.75               ug/g{creat}       0
101994-2 Foundation pain index Find ^Patient Pt Doc Based on lab data   ACTIVE Foundation pain index Document by based on lab data   ADD DefinitionDescription                   CHEM   101994-2   Based on lab data     Both       0 FPI Patient Doc from lab data       N   Chemistry; Document; Finding; Findings; FPI; from lab data; Point in time; Random 2.75 2.75                       0
101995-9 Foundation Pain Index Score Score ^Patient Pt Qn     ACTIVE Foundation Pain Index Score   ADD DefinitionDescription     {score}             CHEM   101995-9         Observation       0 FPI Score Patient       N   Chemistry; FPI; FPI Score; Point in time; QNT; Quan; Quant; Quantitative; Random; Scale 2.75 2.75               {score}       0
101996-7 Erythrocytes.Plasmodium falciparum infected/Erythrocytes NFr Bld Pt Qn Microscopy   ACTIVE Erythrocytes.Plasmodium falciparum infected/Erythrocytes in Blood by Microscopy   NAM DefinitionDescription     %             MICRO   101996-7   Microscopy     Observation       0 P. falciparum RBC/RBC Bld Micro-NFr       N   Blood; Discocytes; Erthrocyte; Erythrocyte; Malaria; Malarial; Micro; Microbiology; Micros; Microscopic; Number fraction; P falciparum; P. falciparum RBC; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; RBC; RBCS; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; WB; Whole blood 2.79 2.75               %     Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; 0
101997-5 Clot initiation.kaolin induced Time Bld Pt Qn Thromboelastography   ACTIVE Clot initiation.kaolin induced [Time] in Blood by Thromboelastography   ADD DefinitionDescription     min             COAG   101997-5   Thromboelastography     Both       0 Clot init kaolin ind Bld TEG       N   Blood; Clot init kao ind p hep neut; Clot init kaolin ind; COAGULATION; CT; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               min       0
101998-3 Clot formation.kaolin induced Time Bld Pt Qn Thromboelastography   ACTIVE Clot formation.kaolin induced [Time] in Blood by Thromboelastography   ADD DefinitionDescription     min             COAG   101998-3   Thromboelastography     Both       0 CFT form kaolin ind Bld TEG       N   Activated clotting time; Blood; CFT; CFT form kaolin ind; Clot time; COAGULATION; Kinetics; k-time; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               min       0
102-4 Cefoperazone Titr Isolate+Ser Pt SemiQn SBT   ACTIVE Cefoperazone [Susceptibility] by Serum bactericidal titer   MAJ DefinitionDescription     titer             ABXBACT   102-4   SBT     Observation       0 Cefoperazone Titr SBT           ANTIBIOTIC SUSCEPTIBILITIES; Cefobid; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Islt; Isol; Point in time; Random; Sequence based typing; Serum; SERUM BACTERICIDAL TITER; Serum killing test; SmQn; SR; Titer; Titered; Titre; Ttr 2.75 1               {titer}       0
1020-7 E Ag PrThr RBC^Donor Pt Ord     ACTIVE E Ag [Presence] on Red Blood Cells from Donor   MAJ DefinitionDescription                   BLDBK   1020-7         Observation       0 E Ag RBC Donr Ql           Antigen; Antigens; BLOOD BANK; Donr; Erythrocytes; Hematology; Heme; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Red blood cells; Red blood corpusles; Rh Blood Group System; Screen 2.56 1                     The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
10200-4 Physical findings Find Heart Pt Nar Observed   ACTIVE Physical findings of Heart Narrative   MIN DefinitionDescription                   H&P.PX   10200-4   Observed             0 Phys find Hrt           Cardiac; Cardio; Cardiology; Exam; Examination; Finding; Findings; H+P; H+P.PX; Heart Disease; Hrt; Narrative; P prime; Phys find; Point in time; Random; Report 2.4 1.0i                       0
102000-7 Maximum clot strength amplitude.kaolin induced Len Bld Pt Qn Thromboelastography   ACTIVE Maximum amplitude kaolin induced [Length] in Blood by Thromboelastography   ADD DefinitionDescription     mm             COAG   102000-7   Thromboelastography     Both       0 MA kaolin Bld TEG       N   Blood; COAGULATION; HKH MA; HKHMA; Length; MA kaolin; MA, HKH; MAK; MAthrombin; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               mm       0
102001-5 Clot initiation.kaolin induced^after addition of heparinase Time Bld Pt Qn Thromboelastography   ACTIVE Clot initiation.kaolin induced [Time] in Blood by Thromboelastography^after addition of heparinase   ADD DefinitionDescription     min             COAG   102001-5   Thromboelastography     Both       0 Clot init kao ind p hep neut p Hpase Bld       N   add heparinase; Blood; Clot init kao ind p hep neut; Clot init kaolin ind; COAGULATION; CT; P Hpase; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               min       0
102002-3 Clot formation.kaolin induced^after addition of heparinase Time Bld Pt Qn Thromboelastography   ACTIVE Clot formation.kaolin induced [Time] in Blood by Thromboelastography^after addition of heparinase   ADD DefinitionDescription     min             COAG   102002-3   Thromboelastography     Both       0 CFT form kaolin ind p Hpase Bld TEG       N   Activated clotting time; add heparinase; Blood; CFT; CFT form kaolin ind; Clot time; COAGULATION; Kinetics; k-time; P Hpase; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               min       0
102003-1 Reduction in clot strength.kaolin induced^30M after maximum clot amplitude after addition of heparinase LenFr Bld Pt Qn Thromboelastography   ACTIVE Reduction in kaolin induced clot strength [Length fraction] in Blood by Thromboelastography ^30 min p max clot amplitude + heparinase   ADD DefinitionDescription     %             COAG   102003-1   Thromboelastography     Both       0 Rd.clot.kaolin.ind 30M p MA hep LenFr B       N   30M p MA p hep; add heparinase; Blood; COAGULATION; Length Fraction; P Hpase; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Red clot kaol; Reduction clot kaolin ind 30M after maxi clot amp after hep; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               %       0
102004-9 Clot angle.kaolin induced^after addition of heparinase Angle Bld Pt Qn Thromboelastography   ACTIVE Clot angle.kaolin induced in Blood by Thromboelastography^after addition of heparinase   ADD DefinitionDescription     deg             COAG   102004-9   Thromboelastography     Both       0 Clot angle.kaolin induced p Hpase Bld TEG       N   add heparinase; Blood; Clot angle kaolin PHpase; COAGULATION; P Hpase; Point in time; QNT; Quan; Quant; Quantitative; Random; TEG; Thrombelastography; Thrombelastometry; WB; Whole blood 2.75 2.75               deg       0
102005-6 Chromium Ab.IgE PrThr Ser Pt SemiQn RAST   ACTIVE Chromium IgE Ab [Presence] in Serum by Radioallergosorbent test (RAST)   NAM DefinitionDescription                   ALLERGY   102005-6   RAST     Both       0 Cr IgE RAST       N   ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; c609; Chrome; CR; Immune globulin E; Immunoglobulin E; Point in time; PR; Radioallergosorbent test; Random; Serum; SmQn; SR 2.78 2.75                     Release 2.78: METHOD_TYP: RAST Method ; SCALE_TYP: changed scale to SemiQn per guidance from the LOINC Lab Committee; 0
102006-4 von Willebrand factor.platelet binding activity without ristocetin ACnc PPP Pt Qn LA   DISCOURAGED von Willebrand factor.platelet binding activity without ristocetin [Units/volume] in Platelet poor plasma by Latex agglutination   MIN DefinitionDescription     arb U/mL     N/A       COAG   102006-4   LA     Both       0 vWf PBA W/O Rist PPP LA-aCnc       N   Activ; Actvty; Arbitrary concentration; Bind; COAGULATION; Fac; Fact; LAT; Latex agglutination; Movements; Pl; Plas; Platelet poor plasma; Platelets; Platelt; Plt; Point in time; QNT; Quan; Quant; Quantitative; Random; Thrombocyte; Thrombocytes; Von will; Vonwillebrand; vWf; vWf PBA W/O Rist 2.79 2.75       AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
102007-2 Heterophile ACTH Interpretation Imp Plas Pt Nar     ACTIVE Heterophile ACTH Interpretation in Plasma Narrative   ADD DefinitionDescription                   CHEM   102007-2         Both       0 Heterophile ACTH Interpretation Plas-Imp       N   Chemistry; Epstein-Barr virus; Hetero; Heteroph; Hetr; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Mono screen; Mono slide; Mono spot; Mono test; Mononucleosis screen; Mononucleosis test; Monospot; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report 2.75 2.75                       0
102008-0 ACTH heterophile Ab interference panel - Plas Pt -     ACTIVE ACTH heterophile Ab interference panel - Plasma   ADD DefinitionDescription                   PANEL.CHEM   102008-0         Order       0 HIACT Plas       N   Chemistry; Epstein-Barr virus; Hetero; Heteroph; Hetr; HIACT; Mono screen; Mono slide; Mono spot; Mono test; Mononucleosis screen; Mononucleosis test; Monospot; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random 2.75 2.75   Panel                   0
102009-8 Laboratory report Find {Setting} Pt Doc Clinical pathology   ACTIVE Clinical pathology Laboratory report   ADD DefinitionDescription                   DOC.ONTOLOGY   102009-8   Clinical pathology     Both       0 Clin Path Laboratory report       N   Clin Path; DOC.ONT; Document; Finding; Findings; Laboratory medicine; Path; Point in time; Random 2.75 2.75                       0
10201-2 Physical findings Find Mouth & Throat & Teeth Pt Nar Observed   ACTIVE Physical findings of Mouth and Throat and Teeth Narrative   MIN DefinitionDescription                   H&P.PX   10201-2   Observed             0 Phys find Mouth+Throat+Teeth           Exam; Examination; Finding; Findings; H+P; H+P.PX; Mouth+Throat; Mouth+Throat+Teeth; Narrative; Oral; P prime; Phys find; Point in time; Random; Report 2.4 1.0i                       0
102010-6 The Primary Care PTSD Screen for DSM-5 - ^Patient Pt - PC-PTSD-5   ACTIVE The Primary Care PTSD Screen for DSM-5 [PC-PTSD-5]   ADD DefinitionDescription                   PANEL.SURVEY.MTLHLTH   102010-6   PC-PTSD-5             0         N   Pan; Panel; PANEL.SURVEY.MTLHLTH; Panl; Pnl; Point in time; Random; Scn; Scr; Scrn; Survey; SURVEY.MTLHLTH 2.75 2.75   Panel                   0
102011-4 Have you experienced a frightening, horrible, or traumatic event Find ^Patient Lifetime Ord PC-PTSD-5   ACTIVE Have you experienced a frightening, horrible, or traumatic event [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102011-4   PC-PTSD-5     Observation       0       Have you experienced a frightening, horrible, or traumatic event? N   Finding; Findings; Ordinal; Ql; Qual; Qualitative; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
102012-2 Have you had nightmares or thoughts about the event(s) when you did not want to Find ^Patient 1Mo Ord PC-PTSD-5   ACTIVE Have you had nightmares or thoughts about the event(s) when you did not want to [PC-PTSD-5]   NAM DefinitionDescription                   SURVEY.MTLHLTH   102012-2   PC-PTSD-5     Observation       0       Have you had nightmares or thoughts about the event(s) when you did not want to? N   1 month; 1 month (30 days); 30 days; Finding; Findings; Ordinal; Ql; Qual; Qualitative; S prime; Screen; Survey; SURVEY.MTLHLTH 2.77 2.75                       0
104,672 results found